2012 ACR/ARHP Annual Meeting

November 9-14, 2012. Washington, DC.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1685

Differential Impact of Cardiac Risk Factors On Coronary Plaque Presence and Features in Asymptomatic Patients with Rheumatoid Arthritis Compared to Controls
Abstract Number: 675

Differential Impairment of Serum Cholesterol Efflux Capacity in Patients with Rheumatoid Arthritis and Systemic Lupus Erythematosus
Abstract Number: 878

Differential Regulation of Cytokines by Extracellular-Signal Regulated Kinase and c-Jun N-Terminal Kinase in Map Kinase Kinase-3 and -6 Deficiency
Abstract Number: 1522

Differential Response to Endoplasmic Reticulum Stress Between Alveolar Epithelial Cells and Lung Fibroblasts in Systemic Sclerosis
Abstract Number: 1737

Diffuse Alveolar Hemorrhage Caused by Primary Antiphospholipid Syndrome
Abstract Number: 1348

Diffuse Idiopathic Skeletal Hyperostosis (DISH) in Psoriatic Arthritis
Abstract Number: 1054

Diffusion Tensor and Dynamic Contrast Enhanced Perfusion Imaging Metrics Discriminate Chronic Tubercular Synovitis From Chronic Inflammatory Synovitis of the Knee
Abstract Number: 934

Direct Medical Cost Associated with Organ System Involvement in a Commercially Insured Population with Systemic Lupus Erythematosus in the United States
Abstract Number: 1418

Directed Intuitive Assessment of Lupus (the DIAL system for real world clinics) Correlates Well with BILAG and SLEDAI
Abstract Number: 2386

Disability and Mortality Related to Cerebrovascular Disease in Systemic Vasculitis
Abstract Number: 2254

Discoid Lupus in Patients with Systemic Lupus Erythematosus
Abstract Number: 771

Discontinuation of Adalimumab without Functional and Radiographic Damage Progression After Achieving Sustained Remission in Patients with Rheumatoid Arthritis (the HONOR study): 1-Year Results
Abstract Number: 402

Discordant Inflammatory Markers in Veterans with Rheumatoid Arthritis: Baseline Characteristics and Relationship with Disease Activity
Abstract Number: 2326

Discovery of a Highly Potent, Selective Reversible Covalent Inhibitor of JAK3 Kinase
Abstract Number: 875

Discovery of Pharmacologic MIF Antagonists by Structure-Based Molecular Design

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].